Accordingly, a monoclonal antibody that blocks PD-L1 binding to the programmed cell death protein-1 (PD-1) receptor on T cells was recently approved by the Food and Drug Administration (FDA) to treat different tumor types and also PD-L1 positive unresectable locally advanced and metastatic TN breast cancer [17,18], since, several studies showed that PD-1 and PD-L1 are overexpressed in the most aggressive cancer subtypes (HER2-positive and triple negative) [19,20,21,22]. Here, ERBB2 is linked to neoplasm.